Clofibrate

Clofibrate

File:Clofibrate.svg
Systematic (IUPAC) name
ethyl 2-(4-chlorophenoxy)-2-methylpropanoate
Clinical data
Pregnancy category	AU: B1 US: C (Risk not ruled out)
Routes of administration	Oral
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Protein binding	Variable, 92–97% at therapeutic concentrations
Metabolism	Hydrolyzed to clofibric acid; hepatic glucuronidation
Biological half-life	Highly variable; average 18–22 hours. Prolonged in renal failure
Excretion	Renal, 95 to 99%
Identifiers
CAS Number	637-07-0
ATC code	C10AB01 (WHO)
PubChem	CID 2796
DrugBank	APRD00879
ChemSpider	2694
Chemical data
Formula	C12H15ClO3
Molar mass	242.698 g/mol[[]]
Physical data
Boiling point	148 to 150 °C (298 to 302 °F)
(verify)

Clofibrate (tradename Atromid-S) is a fibrate. It is a lipid lowering agent used for controlling the high cholesterol and triacylglyceride level in the blood. It increases lipoprotein lipase activity to promote the conversion of VLDL to LDL, and hence reduce the level of VLDL. It is proved that it can increase the level of HDL as well.

It can induce SIADH, syndrome of inappropriate secretion of antidiuretic hormone ADH (vasopressin).

The World Health Organization Cooperative Trial on Primary Prevention of Ischaemic Heart Disease using clofibrate to lower serum cholesterol observed that there was excess mortality in the clofibrate-treated group despite successful cholesterol lowering (47% more deaths during treatment with clofibrate and 5% after treatment with clofibrate) than the non-treated high cholesterol group. These deaths were due to a wide variety of causes other than heart disease, and remain "unexplained".

References

es:Clofibrato